European Commission expands Melflufen's indication for multiple myeloma

The European Commission has expanded the marketing authorization for Pepaxti (melflufen) to include adult patients with multiple myeloma who have received at least two prior lines of therapy and are refractory to lenalidomide and their last therapy. This decision moves the drug's indication from fourth-line to third-line treatment, removing the triple-class refractoriness requirement. This offers an earlier treatment option for eligible patients in Europe.